CHCHD10 Mitochondrial Dysfunction — ALS/FTD Causal Chain

CHCHD10 Mitochondrial Dysfunction — ALS/FTD Causal Chain

Overview

This page traces the causal chain from [CHCHD10](/genes/chchd10) gene mutations to mitochondrial dysfunction and motor neuron degeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). CHCHD10 encodes a mitochondrial intermembrane space protein critical for cristae junction maintenance and oxidative phosphorylation (OXPHOS) complex stability.

Gene Summary

| Property | Value |
|----------|-------|
| Gene Symbol | CHCHD10 |
| Chromosome | 22q11.23 |
| NCBI Gene ID | 400916 |
| OMIM | 615903 |
| Protein | Mitochondrial coiled-coil-helix-coiled-coil-helix domain protein 10 (~14 kDa) |
| Subcellular Location | Mitochondrial intermembrane space, cristae junctions |
| Diseases | ALS, FTD, mitochondrial myopathy, cardiomyopathy, spinal muscular atrophy |

Causal Chain

```mermaid
flowchart TD
A["CHCHD10<br/>Mutations"] --> B["Mitochondrial<br/>Cristae Dysfunction"]
B --> C["OXPHOS<br/>Impairment"]
C --> D["ATP<br/>Depletion"]
B --> E["TDP-43<br/>Mislocalization"]
E --> F["Cytoplasmic<br/>TDP-43 Aggregation"]
D --> G["Motor Neuron<br/>Dysfunction"]
F --> G
C --> H["Mitochondrial<br/>Integrated Stress Response"]
H --> I["Metabolic<br/>Rewiring"]
I --> G
G --> J["Motor Neuron<br/>Death"]
J --> K["ALS/FTD<br/>Phenotype"]

L["Therapeutic<br/>Target"] --> M["Mitochondrial<br/>Protective Agents"]
M -->|"Stabilize"| B

CHCHD10 Mitochondrial Dysfunction — ALS/FTD Causal Chain

Overview

This page traces the causal chain from [CHCHD10](/genes/chchd10) gene mutations to mitochondrial dysfunction and motor neuron degeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). CHCHD10 encodes a mitochondrial intermembrane space protein critical for cristae junction maintenance and oxidative phosphorylation (OXPHOS) complex stability.

Gene Summary

| Property | Value |
|----------|-------|
| Gene Symbol | CHCHD10 |
| Chromosome | 22q11.23 |
| NCBI Gene ID | 400916 |
| OMIM | 615903 |
| Protein | Mitochondrial coiled-coil-helix-coiled-coil-helix domain protein 10 (~14 kDa) |
| Subcellular Location | Mitochondrial intermembrane space, cristae junctions |
| Diseases | ALS, FTD, mitochondrial myopathy, cardiomyopathy, spinal muscular atrophy |

Causal Chain

Chain Element Details

| Chain Element | Description | Evidence |
|---------------|-------------|----------|
| Risk Gene | CHCHD10 — causative gene for ALS-FTD spectrum | Pathogenic variants: S59L, R15L, G66V, G58R, P34S[@bannwarth2014] |
| Molecular Dysfunction | Mitochondrial cristae junction loss, OXPHOS complex instability | Mutations disrupt MICOS complex, leading to cristae disorganization[@genin2016] |
| Downstream Effects | TDP-43 mislocalization, ATP depletion, metabolic rewiring | CHCHD10 LOF causes cytoplasmic TDP-43 accumulation[@woo2017] |
| Clinical Phenotype | Motor neuron degeneration, behavioral FTD, myopathy | Broad phenotypic spectrum from pure ALS to mitochondrial myopathy |

Molecular Mechanism

Step 1: CHCHD10 Mutations

CHCHD10 mutations cause both loss-of-function and toxic gain-of-function effects:

• S59L: Most common pathogenic variant; forms toxic amyloid fibrils with distinct protofilament conformations[@zhou2024]
• R15L, G66V: Disrupt CHCH domain folding and mitochondrial targeting
• G58R: Muscle-restricted phenotype; autosomal dominant mitochondrial myopathy

Step 2: MICOS Complex Disruption

CHCHD10 localizes to mitochondrial cristae junctions where it forms a complex with CHCHD2. This complex stabilizes the MICOS (mitochondrial contact site and cristae organizing system), which is essential for:

• Maintaining cristae morphology
• Ensuring proper OXPHOS complex assembly
• Supporting mitochondrial genome maintenance

Step 3: OXPHOS Impairment

Loss of CHCHD10 function leads to:

• Reduced stability of OXPHOS complexes I and IV
• Impaired mitochondrial respiration
• ATP depletion in metabolically demanding motor neurons

Step 4: TDP-43 Mislocalization

A key link between mitochondrial dysfunction and ALS pathology:

• CHCHD10 loss causes cytoplasmic TDP-43 accumulation
• This is a hallmark pathological feature of ALS/FTD
• Represents a mechanistic link between genetic and sporadic forms

Step 5: Mitochondrial Integrated Stress Response

S59L triggers a distinct metabolic stress response:

• Activation of both mitochondrial and ER unfolded protein responses
• Metabolic rewiring that can be maladaptive
• Tissue-specific effects explain the broad phenotypic spectrum

Step 6: Motor Neuron Degeneration

The final common pathway:

• Energy failure combined with proteostatic stress
• Synaptic dysfunction and dendritic atrophy
• Progressive motor neuron loss leading to ALS/FTD

Therapeutic Implications

Current Therapeutic Approaches

| Approach | Target | Status |
|----------|--------|--------|
| Mitochondrial protective agents | Stabilize cristae, boost OXPHOS | Preclinical |
| Anti-aggregation strategies | Inhibit amyloid fibril formation | Preclinical |
| Metabolic stress response modulators | Modulate ISR, enhance proteostasis | Preclinical |
| PDE4 inhibitors | Reduce CHCHD10 toxicity | FDA-approved drugs being repurposed[@maitra2024] |

Key Therapeutic Targets

Drug Repurposing Opportunities

• PDE4 inhibitors (e.g., Rolipram, Apremilast): Shown to reduce CHCHD10 toxicity in cellular models
• Coenzyme Q10: Supports OXPHOS function
• SS-31 (Bendavia): Mitochondrial-targeted peptide that stabilizes cristae

Comparison to Other ALS/FTD Causal Chains

| Gene | Primary Mechanism | Key Feature |
|------|------------------|-------------|
| CHCHD10 | Mitochondrial cristae dysfunction | TDP-43 link |
| SOD1 | Protein misfolding/aggregation | First ALS gene |
| FUS | RNA processing dysfunction | Nuclear import defect |
| C9orf72 | RNA foci, dipeptide repeat toxicity | Most common genetic cause |
| TDP-43 | TDP-43 aggregation | Sporadic ALS hallmark |
| VCP | Autophagy impairment | Multisystem proteinopathy |
| TBK1 | Autophagy, neuroinflammation | Immune regulation |

CHCHD10 is unique among ALS-FTD genes in directly linking mitochondrial cristae dysfunction to TDP-43 pathology.

Clinical Considerations

Phenotypic Variability

CHCHD10 mutations produce a remarkably broad spectrum:

• Pure ALS: Upper and lower motor neuron signs
• ALS-FTD: Motor neuron disease with behavioral or language FTD
• FTD-only: Behavioral variant or progressive aphasia without motor signs
• Mitochondrial myopathy: Ragged red fibers, COX-negative fibers
• Cardiomyopathy: Cardiac involvement (particularly S59L)
• Spinal muscular atrophy: Late-onset proximal SMA (G66V)

Genetic Testing

CHCHD10 should be included in NGS panels for:

• ALS-FTD overlap cases
• Cases with mitochondrial myopathy features
• Families with autosomal dominant inheritance and variable expressivity

Research Gaps

References

Related Pages

• [CHCHD10 Gene](/genes/chchd10)
• [ALS Genetic Variants](/diseases/als-genetic-variants)
• [FTD Genetic Variants](/diseases/ftd-genetic-variants)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
• [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains)